Navigation Links
New Afatinib (BIBW 2992) Data in Non-Small Cell Lung Cancer Patients Presented at the 2010 ESMO Congress
Date:10/11/2010

RIDGEFIELD, Conn., Oct. 11 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.  In the phase IIb/III LUX-Lung 1 study, afatinib tripled the secondary endpoint of progression free survival (PFS) but did not extend the primary endpoint of overall survival (OS) in late-stage patients with non-small cell lung cancer (NSCLC).(1)      

Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinases.  Afatinib is under development in several solid tumors including NSCLC, breast and head and neck cancer.

The LUX-Lung 1 trial compared afatinib to placebo in over 580 patients with advanced NSCLC who had received chemotherapy and a prior EGFR tyrosine kinase inhibitor (EGFR TKI; gefitinib or erlotinib);(1) results show:

  • Afatinib did not improve OS compared to placebo – 10.78 months vs. 11.96 months, respectively (HR = 1.08, 95% CI 0.86 to 1.35)(1)
  • As a secondary endpoint, afatinib extended PFS three-fold compared to placebo (3.3 months vs. 1.1 months) (HR = 0.38, 95% CI 0.31 to 0.48, p<0.0001).  The improvement in PFS was apparent across all patient subgroups and has been confirmed by independent review(1)
  • At 8 weeks, there was a significantly higher disease control rate (stable disease and tumor shrinkage) in those patients who took afatinib (58%) vs. those taking placebo (19%), which was also independently verified (p<0.0001)(1)
  • Improvement of the lung cancer-related symptoms of cough, dyspnea and pain was observed in the afatinib arm vs. placebo.  In addition, the time to deterioration of cough, individual dyspnea items an
    '/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
4. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
5. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
7. Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer
8. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
11. Human Genome Sciences Completes Enrollment in Randomized Phase 2 Trial of HGS-ETR1 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015  In a sweeping analysis assessing the current ... Exchange researchers conclude that there remains considerable room ... all age groups, but especially for adolescents and young ... diabetes treatment, underscoring the need to address barriers to ... help type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... May 21, 2015 ... announced the addition of the "North ... Replacement, Digit Replacement, Elbow Replacement, Hip Replacement, ... 2019" report to their offering. ,     ... replacement was valued at $4,470.9 million in ...
(Date:5/21/2015)... 2015 Research and ... addition of the "Arthroscopy Devices Markets ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this ... world market for Arthroscopy Devices. The report ... the market for these products. , ,Product ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3
... STXS ) today announced that it will release ... December 31, 2010 on Monday, February 28, 2011 after the ... a conference call and webcast on Monday, February 28, 2011 ... and highlights of the fourth quarter and full year 2010. ...
... Calif., Feb. 9, 2011 On January 26, 2011, ... players were affected so severely by rhabdomyolysis that they ... it suggests an additional causal factor, such as a ... to lower cholesterol, are known in rare cases to ...
Cached Medicine Technology:Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011 2Stereotaxis to Report Fourth Quarter and Full Year 2010 Financial Results and Conduct Conference Call on February 28, 2011 3Did ADHD Drugs Cause Muscle Damage in Iowa Football Players? 2
(Date:5/22/2015)... Pa (PRWEB) May 22, 2015 ... (AHN) today announced a new partnership to develop ... for the region. The initiative includes a new exhibit ... live demonstration theater, and a new traveling science ... the fall of 2015. , Designed to explore ...
(Date:5/22/2015)... VIEW, California (PRWEB) May 22, 2015 Coco ... has set a RecordSetter.com World Record at the 104th running ... Libre coconut water ice luge served 315 people in one ... Bay to Breakers race is so true to the heart ... we felt bringing an ice luge to the finish line ...
(Date:5/22/2015)... NY (PRWEB) May 22, 2015 Medivo, Inc., ... “Positivity Rates and Genotype Results in ‘Baby Boomers’ Screened ... from a Nationwide Lab Test Database” at Digestive Disease Week, ... Medivo’s Clinical Affairs and Analytics team members Carol Smyth, MB; ... and Andrea Parker, MSI, along with Nancy Reau, MD from ...
(Date:5/22/2015)... York, NY (PRWEB) May 22, 2015 Ticket ... Lightning vs. New York Rangers NHL Eastern Conference Finals Tickets ... is together unless specified otherwise in the ticket listing. ... York Rangers are at the top of the Eastern Conference. ... has had its share of ups and downs over the ...
(Date:5/22/2015)... May 22, 2015 A new program ... experts in the field of Physical Therapy. , ... takes the mystery out of physical therapy and discusses ... of motion for a variety of ailments and injuries. ... a personalized exercise plan that enhances daily activities such ...
Breaking Medicine News(10 mins):Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4Health News:Coco Libre Ice Luge Sets New World Record at Bay to Breakers 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 2Health News:Cheap Lightning vs Rangers NHL Eastern Conference Finals Tickets: Ticket Down Slashes Ticket Prices on New York Rangers vs Tampa Bay Lightning Eastern Conference Playoffs 3
... SEATTLE The worst global economic crisis in decades ... record amounts of money to health assistance for developing ... for Health Metrics and Evaluation (IHME) at the University ... health has grown 375% from $5.66 billion in 1990 ...
... obstructive sleep apnea (OSA), a sleep disorder associated with ... coronary arteries, according to a study presented today at ... America (RSNA). "Our study reveals that individuals with ... form of atherosclerosis that puts them at risk for ...
... say they have found an effective two-part treatment for microtears ... a steroid along with "dry-needling," in which repeated needle punctures ... the study were presented today at the annual meeting of ... the patient,s own blood where it is needed at the ...
... CHICAGO Using functional magnetic resonance imaging (fMRI), researchers ... a pain stimulus with and without acupuncture to determine ... of the study, which the researchers say suggest the ... meeting of the Radiological Society of North America (RSNA). ...
... CA, November 30, 2010 In the wake of multiple ... warning to four companies to remove their products from the ... of Preventive Medicine delineates the scope of the public health ... it. "Although several manufacturers of caffeinated beer have withdrawn ...
... (November 29, 2010) Whitehead Institute researchers have shown ... (miR-125b) can independently cause leukemia and accelerate the disease,s ... edition of the Proceedings of the National Academy of ... but in humans and mice, can upregulation of a ...
Cached Medicine News:Health News:Despite economic slump, donors give generously to global health, though at a slower rate 2Health News:Despite economic slump, donors give generously to global health, though at a slower rate 3Health News:People with sleep apnea at higher risk for aggressive heart disease 2Health News:Researchers use patient's own blood to treat hamstring injury 2Health News:Acupuncture changes brain's perception and processing of pain 2Health News:Caffeinated alcoholic beverages -- a growing public health problem 2Health News:Tiny RNA shown to cause multiple types of leukemia 2Health News:Tiny RNA shown to cause multiple types of leukemia 3
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. The procedure can be done in the office under topical anesthesia. Complete Set Includes Vacuum Speculum, ...
... of temporary sensing and pacing leads. Our ... temporary pacing leads and improved upon the ... and less traumatic to heart tissue. , ... to provide consistent temporary sensing and pacing ...
... indication for this technique is acquired ... Indications for tricuspid repair are based ... as diagnosed by angiography and dye ... In patients with an irreversible tricuspid ...
... Pro Medical Billing proudly offers distinct ... your area of expertise. ... diagnosis codes and medical records templates ... practice, ob/gyn, sports medicine, ophthalmology, allergy, ...
Medicine Products: